The SITC Spring Scientific, Cellular Therapy for Solid Tumors, will address the recent advances in adoptive cellular therapy for solid tumors and rate-limiting challenges that impede bringing these novel therapies to patients in need. The program will feature in-depth discussions of the latest scientific insights and advances in the field and unique opportunities and unanswered questions in the areas of target antigen selection, product design, and therapeutic efficacy and safety.
SITC will bring the brightest minds and the next generation of leaders together to explore the more promising science and develop novel opportunities to address these challenges.
Target Audience
The target audience for this program includes clinical, basic, and translational researchers from academic, industry, or government settings interested in exploring differences between hematologic malignancies and solid tumors, synthetic versus endogenous immunity, and in vivo cell therapy with a focus on emerging platform technologies.